| (Q1) At present, NVAF can be treated with NOACs, while for valvular AF the only therapeutic resource is VKAs. Make an estimate of the percentage of patients with AF in clinical practice that will still require therapy with VKAs because suffering from valvular AF . | Cardiologists . | Internists . | ||
|---|---|---|---|---|
| n (%) . | 95% CI . | n (%) . | 95% CI . | |
| <5% | 21 (7.7) | (4.8–11.5) | 33 (13.8) | (9.7–18.8) |
| 5–9% | 68 (24.9) | (19.9–30.5) | 52 (21.7) | (16.6– 27.4) |
| 10–19% | 51 (18.7) | (14.2–23.8) | 40 (16.7) | (12.2–22.0) |
| >20% | 51 (18.7) | (14.2–23.8) | 33 (13.8) | (9.7–18.8) |
| No answer | 82 (30.0) | (24.7–35.9) | 82 (34.2) | (28.2–40.5) |
| Total | 273 (100.0) | 240 (100.0) | ||
| (Q1) At present, NVAF can be treated with NOACs, while for valvular AF the only therapeutic resource is VKAs. Make an estimate of the percentage of patients with AF in clinical practice that will still require therapy with VKAs because suffering from valvular AF . | Cardiologists . | Internists . | ||
|---|---|---|---|---|
| n (%) . | 95% CI . | n (%) . | 95% CI . | |
| <5% | 21 (7.7) | (4.8–11.5) | 33 (13.8) | (9.7–18.8) |
| 5–9% | 68 (24.9) | (19.9–30.5) | 52 (21.7) | (16.6– 27.4) |
| 10–19% | 51 (18.7) | (14.2–23.8) | 40 (16.7) | (12.2–22.0) |
| >20% | 51 (18.7) | (14.2–23.8) | 33 (13.8) | (9.7–18.8) |
| No answer | 82 (30.0) | (24.7–35.9) | 82 (34.2) | (28.2–40.5) |
| Total | 273 (100.0) | 240 (100.0) | ||
In the table, the number of subjects, the percentage, and corresponding 95% confidence interval (95% CI) are reported for each modality of response.
| (Q1) At present, NVAF can be treated with NOACs, while for valvular AF the only therapeutic resource is VKAs. Make an estimate of the percentage of patients with AF in clinical practice that will still require therapy with VKAs because suffering from valvular AF . | Cardiologists . | Internists . | ||
|---|---|---|---|---|
| n (%) . | 95% CI . | n (%) . | 95% CI . | |
| <5% | 21 (7.7) | (4.8–11.5) | 33 (13.8) | (9.7–18.8) |
| 5–9% | 68 (24.9) | (19.9–30.5) | 52 (21.7) | (16.6– 27.4) |
| 10–19% | 51 (18.7) | (14.2–23.8) | 40 (16.7) | (12.2–22.0) |
| >20% | 51 (18.7) | (14.2–23.8) | 33 (13.8) | (9.7–18.8) |
| No answer | 82 (30.0) | (24.7–35.9) | 82 (34.2) | (28.2–40.5) |
| Total | 273 (100.0) | 240 (100.0) | ||
| (Q1) At present, NVAF can be treated with NOACs, while for valvular AF the only therapeutic resource is VKAs. Make an estimate of the percentage of patients with AF in clinical practice that will still require therapy with VKAs because suffering from valvular AF . | Cardiologists . | Internists . | ||
|---|---|---|---|---|
| n (%) . | 95% CI . | n (%) . | 95% CI . | |
| <5% | 21 (7.7) | (4.8–11.5) | 33 (13.8) | (9.7–18.8) |
| 5–9% | 68 (24.9) | (19.9–30.5) | 52 (21.7) | (16.6– 27.4) |
| 10–19% | 51 (18.7) | (14.2–23.8) | 40 (16.7) | (12.2–22.0) |
| >20% | 51 (18.7) | (14.2–23.8) | 33 (13.8) | (9.7–18.8) |
| No answer | 82 (30.0) | (24.7–35.9) | 82 (34.2) | (28.2–40.5) |
| Total | 273 (100.0) | 240 (100.0) | ||
In the table, the number of subjects, the percentage, and corresponding 95% confidence interval (95% CI) are reported for each modality of response.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
